Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects

QR Code

Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects

The bile acid taurocholic acid (TCA) is endogenously produced, and has shown formulation-stabilising effects when incorporated into microcapsules containing potential antidiabetic drugs. This study aimed to develop and characterise TCA-microcapsules, and test their antidiabetic effects, in an animal...

Full description

Bibliographic Details
Main Authors:	Mathavan, S., Mikov, M., Golocorbin-Kon, S., Al-Salami, Hani
Format:	Journal Article
Published:	Elsevier Science 2017
Online Access:	http://hdl.handle.net/20.500.11937/53770

Similar Items

The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study
by: Mooranian, A., et al.
Published: (2015)

High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect
by: Golocorbin-Kon, S., et al.
Published: (2017)

An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations
by: Mooranian, A., et al.
Published: (2015)

Application of bile acids in drug formulation and delivery
by: Stojancevic, M., et al.
Published: (2014)

The applications of microencapsulated formulation of gliclazide and bile acids in Type-1 diabetes mellitus
by: Mathavan, Sangeetha
Published: (2017)

Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2012)

Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid
by: Mathavan, S., et al.
Published: (2018)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
by: Mooranian, Armin, et al.
Published: (2015)

Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
by: Danic, M., et al.
Published: (2018)

Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
by: Mooranian, Armin, et al.
Published: (2014)

Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles
by: Pavlovic, N., et al.
Published: (2018)

The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus
by: Woodhams, L., et al.
Published: (2017)

Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid
by: Mooranian, A., et al.
Published: (2018)

Bile acids and probiotics could help treating diabetes
by: Calasan, J., et al.
Published: (2012)

Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics
by: Mikov, M., et al.
Published: (2017)

An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
by: Mooranian, Armin, et al.
Published: (2014)

Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study
by: Mooranian, A., et al.
Published: (2015)

Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
by: Mooranian, Armin, et al.
Published: (2014)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment (vol 32, pg 151, 2014)
by: Mooranian, A., et al.
Published: (2015)

Advanced bile acid-based multi-compartmental microencapsulated pancreatic ß-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.
by: Mooranian, A., et al.
Published: (2014)

Novel artificial cell microencapsulation of probucol and bile acids in diabetes mellitus
by: Mooranian, Armin
Published: (2018)

Viability and topographical analysis of microencapsulated ß-cells exposed to a biotransformed tertiary bile acid: An ex vivo study
by: Mooranian, Armin, et al.
Published: (2016)

Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System
by: Negrulj, Rebecca, et al.
Published: (2013)

Physicochemical, in vitro bile-acid binding and hypoglycaemic properties of red pitaya (Hylocereus polyrhizus) peel pectin
by: Al-Ezzi, Majida, et al.
Published: (2024)

The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes
by: Mathavan, S., et al.
Published: (2015)

Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics
by: Mooranian, Armin, et al.
Published: (2014)

Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics
by: Al-Salami, Hani, et al.
Published: (2008)

Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine ß-cell Survival and the Inflammatory Response
by: Mooranian, A., et al.
Published: (2016)

Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes
by: Mooranian, Armin, et al.
Published: (2018)

Taurocholate Induces Biliary Differentiation of Liver Progenitor Cells Causing Hepatic Stellate Cell Chemotaxis in the Ductular Reaction: Role in Pediatric Cystic Fibrosis Liver Disease
by: Pozniak, K., et al.
Published: (2017)

Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes
by: Negrulj, R., et al.
Published: (2015)

The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes
by: Mooranian, Armin, et al.
Published: (2016)

THE EFFECT OF BILE ACID SALT SODIUM 3ALPHA, 7ALPHA-DIHYDROXY-12-KETO-5BETA-CHOLANATE (MKC) AND PROBIOTIC PRETREATMENT ON GLICLAZIDE PERMEATION IN ILEAL TISSUES FROM HEALTHY AND DIABETIC RATS
by: Mikov, M., et al.
Published: (2014)

A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes
by: Mathavan, Sangeetha, et al.
Published: (2015)

Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat
by: Lalic-Popovic, M., et al.
Published: (2013)

Novel multicompartmental bile acid-based microcapsules for pancreatic β-cell transplantation
by: Mooranian, A., et al.
Published: (2015)

Extraction and quantitative determination of bile acids in feces
by: Shafaei, A., et al.
Published: (2021)

New biotechnological microencapsulating methodology utilizing individualized gradient-screened jet laminar flow techniques for pancreatic ß-cell delivery: bile acids support cell energy-generating mechanisms
by: Mooranian, A., et al.
Published: (2017)

Alginate-combined cholic acid increased insulin secretion of microencapsulated mouse cloned pancreatic ß cells
by: Mooranian, A., et al.
Published: (2017)

Lipid components of bile increase the protective effect of conjugated bile salts against antifungal drugs
by: Hsieh, Shih-Hung, et al.
Published: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ia9gkkf4f2s5cvcli78eijfg8c